このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Rhythm Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Rhythm Pharmaceuticals'の CEO はDavid Meekerで、 Jul2020年に任命され、 の在任期間は 3.92年です。 の年間総報酬は$ 7.23Mで、 9.7%給与と90.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.29%を直接所有しており、その価値は$ 7.19M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と5年です。
主要情報
David Meeker
最高経営責任者
US$7.2m
報酬総額
| CEO給与比率 | 9.7% |
| CEO在任期間 | 4yrs |
| CEOの所有権 | 0.3% |
| 経営陣の平均在職期間 | 3.7yrs |
| 取締役会の平均在任期間 | 5.1yrs |
経営陣の近況
Recent updates
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$274m |
| Dec 31 2023 | US$7m | US$705k | -US$185m |
| Sep 30 2023 | n/a | n/a | -US$186m |
| Jun 30 2023 | n/a | n/a | -US$182m |
| Mar 31 2023 | n/a | n/a | -US$181m |
| Dec 31 2022 | US$3m | US$652k | -US$181m |
| Sep 30 2022 | n/a | n/a | -US$181m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$166m |
| Dec 31 2021 | US$6m | US$630k | -US$70m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$15m | US$262k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$134m |
| Mar 31 2020 | n/a | n/a | -US$146m |
| Dec 31 2019 | US$287k | n/a | -US$141m |
| Sep 30 2019 | n/a | n/a | -US$133m |
| Jun 30 2019 | n/a | n/a | -US$115m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$282k | n/a | -US$74m |
| Sep 30 2018 | n/a | n/a | -US$59m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$268k | n/a | -US$38m |
報酬と市場: Davidの 総報酬 ($USD 7.23M ) は、 US市場 ($USD 6.83M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Davidの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
David Meeker (70 yo)
4yrs
在職期間
US$7,230,457
報酬
Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 4yrs | US$7.23m | 0.29% $ 7.2m | |
| CFO & Treasurer | 7yrs | US$2.31m | 0.16% $ 4.0m | |
| Chief Technical Officer | 4yrs | US$1.74m | 0.000050% $ 1.3k | |
| Executive VP & Head of International | 3.8yrs | US$1.74m | 0.057% $ 1.4m | |
| Executive VP & Head of North America | 3.7yrs | US$2.11m | 0.011% $ 281.4k | |
| Corporate Controller | 1.3yrs | データなし | 0.0013% $ 32.5k | |
| Head of Investor Relations & Corporate Communications | no data | データなし | データなし | |
| Senior VP & General Counsel | 3.7yrs | データなし | データなし | |
| Vice President of Sales & Marketing | no data | データなし | データなし | |
| Chief Human Resources Officer | 3yrs | データなし | 0.049% $ 1.2m | |
| Senior VP & Head of Strategy | 2.4yrs | データなし | データなし | |
| Senior Vice President of Clinical Development | 1.8yrs | データなし | データなし |
3.7yrs
平均在職期間
52yo
平均年齢
経験豊富な経営陣: RYTMの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 8.7yrs | US$7.23m | 0.29% $ 7.2m | |
| Corporate Controller | 1.3yrs | データなし | 0.0013% $ 32.5k | |
| Independent Director | 5.1yrs | US$283.77k | 0.0049% $ 123.2k | |
| Independent Director | 8.7yrs | US$308.77k | 0.0049% $ 123.2k | |
| Lead Independent Director | 11.3yrs | US$328.77k | 0.014% $ 360.3k | |
| Independent Director | 3.6yrs | US$298.77k | 0.0049% $ 123.2k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Chairman of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 5yrs | US$301.27k | 0.0049% $ 123.2k |
5.1yrs
平均在職期間
67yo
平均年齢
経験豊富なボード: RYTMの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。